Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
LTL Pharma has sealed a deal earlier this year to take over Sanofi’s anti-allergy agent Dellegra (fexofenadine + pseudoephedrine) in Japan, and it wants to capitalize on the product to build a track record in handling medicines that have just…
To read the full story
Related Article
- LTL Pharma to License Dellegra AG to Nichi-Iko, Eyeing December Rollout
September 3, 2020
- LTL Pharma to Take Over Sanofi’s Dellegra in Japan
August 5, 2020
BUSINESS
- Sanofi to Launch Voluntary Buyout Program, Targets General Medicines Unit
April 7, 2026
- Toho’s VC Arm Makes First Investment in US AI Antibody Startup
April 7, 2026
- Keytruda Holds Top Spot for 30 Straight Months in March: Encise
April 7, 2026
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…